Clinical data | |
---|---|
Trade names | Zanosar |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684053 |
Routes of administration | Intravenous |
Drug class | Alkylating agent[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 17–25% (100% if IV) |
Metabolism | Liver, kidney |
Elimination half-life | 35–40 minutes |
Identifiers | |
| |
Chemical and physical data | |
Formula | C8H15N3O7 |
Molar mass | 265.222 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Streptozotocin, also known as streptozocin (STZ), is a medication used for treating certain islet cell cancer of the pancreas, carcinoid tumor, and pancreatic adenocarcinoma.[1] It is given by injection into a vein.[1]
Common side effects include nausea, kidney problems, and bone marrow suppression.[1] Other side effects may include liver problems, confusion, and pain at the site of injection.[1] Use during pregnancy may harm the baby.[1] It is a alkylating agent.[1]
Streptozotocin was approved for medical use in the United States in 1982.[1] In the United Kingdom it cost the NHS about £570 per 1 gram as of 2021.[2] This amount in the United States costs about 370 USD.[3] It is sold under the brand name Zanosar among others.[1]
References edit
- ^ a b c d e f g h i j k "Streptozocin Monograph for Professionals". Drugs.com. Archived from the original on 7 September 2015. Retrieved 14 October 2021.
- ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 949. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link) - ^ "Zanosar Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 15 October 2021.